Top

Published in:

01-07-2013 | Review Article

Therapeutic Management of Primary Immunodeficiency in Older Patients

Authors: Nisha Verma, Anthony Thaventhiran, Benjamin Gathmann, James Thaventhiran, Bodo Grimbacher, for the ESID Registry Working Party

Published in: Drugs & Aging | Issue 7/2013

Abstract

Primary immunodeficiency disease (PID) has traditionally been viewed as a group of illnesses seen in the paediatric age group. New advances in diagnosis and treatment have led to an increase in the number of elderly PID patients. However, there is lack of research evidence on which to base clinical management in this group of patients. Management decisions often have to be based therefore on extrapolations from other patient cohorts or from younger patients. Data from the European Society for Immunodeficiencies demonstrates that the vast majority of elderly patients suffer from predominantly antibody deficiency syndromes. We review the management of PID disease in the elderly, with a focus on antibody deficiency disease.

Notarangelo LD, Fischer A, Geha RS, Casanova JL, Chapel H, Conley ME, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124(6):1161–78.PubMedCrossRef

McEwan WA, Mallery DL, Rhodes DA, Trowsdale J, James LC. Intracellular antibody-mediated immunity and the role of TRIM21. BioEssays. 2011;33(11):803–9. doi:10.1002/bies.201100093. (Epub 2011 Aug 29).PubMedCrossRef

Cowan MJ, Neven B, Cavazanna-Calvo M, Fischer A, Puck J. Hematopoietic stem cell transplantation for severe combined immunodeficiency diseases. Biol Blood Marrow Transpl. 2008;14(1 Suppl 1):73–5.CrossRef

Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med. 1993;86(1):31–42.PubMed

Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92(1):34–48.PubMedCrossRef

Winkelstein JA, Marino MC, Lederman HM, Jones SM, Sullivan K, Burks AW, et al. X-linked agammaglobulinemia: report on a United States registry of 201 patients. Medicine. 2006;85(4):193–202.PubMedCrossRef

Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8.PubMed

Kornfeld SJ, Haire RN, Strong SJ, Tang H, Sung SS, Fu SM, et al. A novel mutation (Cys145–>Stop) in Bruton’s tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male. Molecular Med. 1996;2(5):619–23.

Plebani A, Soresina A, Rondelli R, Amato GM, Azzari C, Cardinale F, et al. Clinical, immunological, and molecular analysis in a large cohort of patients with X-linked agammaglobulinemia: an Italian multicenter study. Clin Immunol. 2002;104(3):221–30.PubMedCrossRef

10.

Schaffer AA, Salzer U, Hammarstrom L, Grimbacher B. Deconstructing common variable immunodeficiency by genetic analysis. Current Opin Genet Dev. 2007;17(3):201–12.CrossRef

11.

Di Renzo M, Pasqui AL, Auteri A. Common variable immunodeficiency: a review. Clin Exp Med. 2004;3(4):211–7.PubMedCrossRef

12.

Eades-Perner AM, Gathmann B, Knerr V, Guzman D, Veit D, Kindle G, et al. The European internet-based patient and research database for primary immunodeficiencies: results 2004–06. Clin Exp Immunol. 2007;147(2):306–12.PubMedCrossRef

13.

De Santis W, Esposito A, Conti V, Fantauzzi A, Guerra A, Mezzaroma I, et al. Health care and infective aspects in patients affected by common variable immunodeficiency assisted in the Lazio Regional Authority Reference Centre for Primary Immunodeficiencies. Infez Med. 2006;14(1):13–23.PubMed

14.

Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol. 1999;93(3):190–7.PubMedCrossRef

15.

Bonilla FA, Bernstein IL, Khan DA, Ballas ZK, Chinen J, Frank MM, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol. 2005;94(5 Suppl 1):S1–63.PubMedCrossRef

16.

Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol. 2011;165(1):1–7. doi:10.1111/j.1365-2249.2011.04384.x. (Epub 2011 Apr 6).PubMedCrossRef

17.

Correa P, Houghton JM. Carcinogenesis of Helicobacter pylori. Gastroenterology. 2007;133:659–72.PubMedCrossRef

18.

Zullo A, Romiti A, Rinaldi V, Vecchione A, Tomao S, Aiuti F, Frati L, Luzi G. Gastric pathology in patients with common variable immunodeficiency. Gut. 1999;45(1):77–81.PubMedCrossRef

19.

Cunnigham-Rundles C, Cooper DL, Duffy TP, Strauchen J. Lymphomas of mucosal associated lymphoid tissue in common variable immunodeficiency. Am J Hematol. 2002;69(3):171–8.CrossRef

20.

Aghamohammadi A, Parvaneh N, Tirgari F, Mahjoob F, Movahedi M, Gharagozlou M, Mansouri M, Kouhi A, Rezaei N, Webster D. Lymphoma of mucosa-associated lymphoid tissue in common variable immunodeficiency. Leuk Lymphoma. 2006;47(2):343–6. (Review).PubMedCrossRef

21.

Park MA, Li JT, Hagan JB, Maddox DE, Abraham RS. Common variable immunodeficiency: a new look at an old disease. Lancet. 2008;372(9637):489–502.PubMedCrossRef

22.

Mellemkjaer L, Hammarstrom L, Andersen V, Yuen J, Heilmann C, Barington T, et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol. 2002;130(3):495–500.PubMedCrossRef

23.

Spector BD, Perry GS, 3rd, Gajl-Peczalska KJ, Coccia P, Nesbit ME, Kersey JH. Malignancy in children with and without genetically-determined immunodeficiencies. Birth Defects Orig Artic Ser. 1978;14(6A):85–9.PubMed

24.

Kainulainen L, Varpula M, Liippo K, Svedstrom E, Nikoskelainen J, Ruuskanen O. Pulmonary abnormalities in patients with primary hypogammaglobulinemia. J Allergy Clin Immunol. 1999;104(5):1031–6.PubMedCrossRef

25.

Sodickson A, Baeyens PF, Andriole KP, Prevedello LM, Nawfel RD, Hanson R, Khorasani R. Recurrent CT, cumulative radiation exposure, and associated radiation-induced cancer risks from CT of adults. Radiology. 2009;251(1):175–84.PubMedCrossRef

26.

Yong PF, Tarzi M, Chua I, Grimbacher B, Chee R. Common variable immunodeficiency: an update on etiology and management. Immunol Allergy Clin N Am. 2008;28(2):367–86, ix-x.

27.

Quinti I, Soresina A, Spadaro G, Martino S, Donnanno S, Agostini C, et al. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J Clin Immunol. 2007;27(3):308–16.PubMedCrossRef

28.

Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun. 2005;25(1):57–62.PubMedCrossRef

29.

Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, Vlkova M, Hernandez M, Detkova D, Bos PR, Poerksen G, von Bernuth H, Baumann U, Goldacker S, Gutenberger S, Schlesier M, Bergeron-van der Cruyssen F, Le Garff M, Debré P, Jacobs R, Jones J, Bateman E, Litzman J, van Hagen PM, Plebani A, Schmidt RE, Thon V, Quinti I, Espanol T, Webster AD, Chapel H, Vihinen M, Oksenhendler E, Peter HH, Warnatz K. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008;111(1):77–85 (Epub 2007 Sep 26).

30.

Sordet C, Cantagrel A, Schaeverbeke T, Sibilia J. Bone and joint disease associated with primary immune deficiencies. Joint Bone Spine. 2005;72(6):503–14.PubMedCrossRef

31.

Wang LJ, Yang YH, Lin YT, Chiang BL. Immunological and clinical features of pediatric patients with primary hypogammaglobulinemia in Taiwan. Asian Pac J Allergy Immunol. 2004;22(1):25–31.PubMed

32.

Kelesidis T, Yang O. Good’s syndrome remains a mystery after 55 years: a systematic review of the scientific evidence. Clin Immunol. 2010;135(3):347–63.PubMedCrossRef

33.

Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. International Union of Immunological Societies. Clin Exp Immunol. 1999;118(Suppl 1):1–28.

34.

Kaveri SV, Maddur MS, Hegde P, Lacroix-Desmazes S, Bayry J. Intravenous immunoglobulins in immunodeficiencies: more than mere replacement therapy. Clin Exp Immunol. 2011;164(Suppl 2):2–5.PubMedCrossRef

35.

de Gracia J, Vendrell M, Alvarez A, Pallisa E, Rodrigo MJ, de la Rosa D, et al. Immunoglobulin therapy to control lung damage in patients with common variable immunodeficiency. Int Immunopharmacol. 2004;4(6):745–53.PubMedCrossRef

36.

Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20(2):94–100.PubMedCrossRef

37.

Stein MR, Koterba A, Rodden L, Berger M. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases. Postgrad Med. 2011;123(5):186–93.PubMedCrossRef

38.

Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101(2):114–21. (Quiz 22–3, 78).PubMedCrossRef

39.

Wood PM. Primary antibody deficiency syndromes. Current Opin Hematol. 2010;17(4):356–61.CrossRef

40.

Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, Bonilla FA, Buckley R, Chinen J, El-Gamal Y, Mazer BD, Nelson RP Jr, Patel DD, Secord E, Sorensen RU, Wasserman RL, Cunningham-Rundles C, Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2006;117(4 Suppl):S525–53.

41.

Hamrock DJ. Adverse events associated with intravenous immunoglobulin therapy. Int Immunopharmacol. 2006;6(4):535–42.PubMedCrossRef

42.

Caress JB, Kennedy BL, Eickman KD. Safety of intravenous immunoglobulin treatment. Expert Opin Drug Safety. 2006;9(6):971–9.CrossRef

43.

Cheng MJ, Christmas C. Special considerations with the use of intravenous immunoglobulin in older persons. Drugs Aging. 2011;28(9):729–36.PubMedCrossRef

44.

Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis. 2005;16(5):313–8.PubMedCrossRef

45.

Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol. 2009;256(3):339–42.PubMedCrossRef

46.

Hoiby N, Frederiksen B, Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros. 2005;4(Suppl 2):49–54.PubMedCrossRef

47.

Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988–98.PubMedCrossRef

48.

Hoiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 2011;9:32.PubMedCrossRef

49.

Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2007(3):CD005590.

50.

Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol. 2010;125(6):1354–60.e4. (Epub 2010 May 14).

51.

Longhurst HJ, Taussig D, Haque T, Syndercombe-Court D, Cavenagh J, Edgar JD, et al. Non-myeloablative bone marrow transplantation in an adult with Wiskott–Aldrich syndrome. Br J Haematol. 2002;116(2):497–9.PubMedCrossRef

52.

Rizzi M, Neumann C, Fielding AK, Marks R, Goldacker S, Thaventhiran J, et al. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J Allergy Clin Immunol. 2011;128(6):1371–4.e2.

53.

Marodi L, Notarangelo LD. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev. 2007;7(11):851–61.CrossRef

54.

Yong PF, Thaventhiran JE, Grimbacher B. “A rose is a rose is a rose,” but CVID is not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv Immunol. 2011;111:47–107.PubMedCrossRef

55.

Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355–64.PubMedCrossRef

56.

Alcais A, Quintana-Murci L, Thaler DS, Schurr E, Abel L, Casanova JL. Life-threatening infectious diseases of childhood: single-gene inborn errors of immunity? Ann N Y Acad Sci. 2010;1214:18–33.PubMedCrossRef

Title: Therapeutic Management of Primary Immunodeficiency in Older Patients
Authors: Nisha Verma
Anthony Thaventhiran
Benjamin Gathmann
James Thaventhiran
Bodo Grimbacher
for the ESID Registry Working Party
Publication date: 01-07-2013
Publisher: Springer International Publishing AG
Published in: Drugs & Aging / Issue 7/2013
Print ISSN: 1170-229X
Electronic ISSN: 1179-1969
DOI: https://doi.org/10.1007/s40266-013-0079-7

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Therapeutic Management of Primary Immunodeficiency in Older Patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Management Options for Refractory Chronic Myeloid Leukemia: Considerations for the Elderly

Polypharmacy and Potentially Inappropriate Medication in the Adult, Community-Dwelling Population in Switzerland

Patterns and Determinants of Dementia Pharmacotherapy in a Population-Based Cohort of Home Care Clients

Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly

Sulfonylureas and Risk of Falls and Fractures: A Systematic Review

Combined Olmesartan, Amlodipine, and Hydrochlorothiazide Therapy in Randomized Patients with Hypertension: A Subgroup Analysis of the TRINITY Study by Age

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page